56. Behcet disease
68 clinical trials,   87 drugs   (DrugBank: 31 drugs),   36 drug target genes,   113 drug target pathways

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02648581
(ClinicalTrials.gov)
June 14, 201721/12/2015Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseA Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseBehçet DiseaseDrug: Subcutaneous UstekinumabAssistance Publique - Hôpitaux de ParisNULLActive, not recruiting18 YearsN/AAll16Phase 2France
2EUCTR2015-002190-37-FR
(EUCTR)
30/10/201512/01/2016A Study to Evaluate the Efficacy and Safety of Ustekinumab in patients with Behçet diseaseA Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in patients with Behçet disease : STELABEC - STELABEC Behçet diseaseSTELABEC-1: patients with oral ulcersSTELABEC-2 : patients with active posterior uveitis or panuveitis
MedDRA version: 18.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: STELARA
Product Name: STELARA
INN or Proposed INN: Ustekinumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
30Phase 2France